Open AccessFDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T‐Cell Lymphoma
Author(s) -
Mann Bhupinder S.,
Johnson John R.,
Cohen Martin H.,
Justice Robert,
Pazdur Richard
Publication year - 2007
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.12-10-1247
Subject(s) - medicine , vorinostat , cutaneous t cell lymphoma , lymphoma , oncology , mycosis fungoides , immunology , biochemistry , chemistry , histone deacetylase , gene , histone
Learning Objectives After completing this course, the reader will be able to: Add vorinostat to the armamentarium of drugs for CTCL. Identify the mechanism of action of vorinostat. Identify goals of therapy of CTCL. Identify active CTCL therapies. Identify CTCL response criteria.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com